Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate is a drug owned by Santarus Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 16, 2016. Details of Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6489346 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(9 years ago) |
Expired
|
| US7399772 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(9 years ago) |
Expired
|
| US6645988 | Substituted benzimidazole dosage forms and method of using same |
Jul, 2016
(9 years ago) |
Expired
|
| US6699885 | Substituted benzimidazole dosage forms and methods of using same |
Jul, 2016
(9 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate's patents.
Latest Legal Activities on Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate's Patents
Given below is the list of recent legal activities going on the following patents of Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent
Critical | 17 Aug, 2020 | US7399772 (Litigated) |
| Maintenance Fee Reminder Mailed
Critical | 02 Mar, 2020 | US7399772 (Litigated) |
| Patent Issue Date Used in PTA Calculation
Critical | 15 Jul, 2008 | US7399772 (Litigated) |
| Recordation of Patent Grant Mailed
Critical | 15 Jul, 2008 | US7399772 (Litigated) |
| Issue Notification Mailed
Critical | 25 Jun, 2008 | US7399772 (Litigated) |
| Dispatch to FDC | 16 Jun, 2008 | US7399772 (Litigated) |
| Application Is Considered Ready for Issue
Critical | 04 Jun, 2008 | US7399772 (Litigated) |
| Issue Fee Payment Verified
Critical | 03 Jun, 2008 | US7399772 (Litigated) |
| Mail Miscellaneous Communication to Applicant | 03 Jun, 2008 | US7399772 (Litigated) |
| Issue Fee Payment Received
Critical | 03 Jun, 2008 | US7399772 (Litigated) |
US patents provide insights into the exclusivity only within the United States, but
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate's family patents as well as insights into
ongoing legal events
on those patents.
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 16, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate Generics:
There are no approved generic versions for Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate as of now.
Alternative Brands for Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate which is used for treating various gastrointestinal conditions such as ulcers, heartburn, and GERD., has several other brand drugs in the same treatment category and using the same active ingredient (Magnesium Hydroxide; Omeprazole; Sodium Bicarbonate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Salix |
| |||
| Santarus |
| |||
About Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate is a drug owned by Santarus Inc. It is used for treating various gastrointestinal conditions such as ulcers, heartburn, and GERD. Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate uses Magnesium Hydroxide; Omeprazole; Sodium Bicarbonate as an active ingredient. Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate was launched by Santarus in 2009.
Approval Date:
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate was approved by FDA for market use on 04 December, 2009.
Active Ingredient:
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate uses Magnesium Hydroxide; Omeprazole; Sodium Bicarbonate as the active ingredient. Check out other Drugs and Companies using Magnesium Hydroxide; Omeprazole; Sodium Bicarbonate ingredient
Treatment:
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate is used for treating various gastrointestinal conditions such as ulcers, heartburn, and GERD.
Dosage:
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 343MG;40MG;750MG | TABLET | Discontinued | ORAL |
| 343MG;20MG;750MG | TABLET | Discontinued | ORAL |